Dupilumab Dampens Mucosal Type 2 Response During Acetylsalicylic Acid Challenge in N-ERD Patients.

While nasal baseline leukotriene levels showed a trend towards reduction after dupilumab treatment (Table S3 ), as previously shown [ 15 ], we were surprised that N‐ERD patients still expressed substantial amounts of LTE 4 after the second ASA provocation (Figure 4A and Figure S5A ).

also in 53,322 other papers